Strong evidence exists to support the use of statins, acetylsalicylic acid (ASA) and angiotensin-converting enzyme inhibitors (ACEI) in patients at high risk of cardiovascular (CV) events; however, current practice pattern data indicate that a significant care gap exists between evidence and practice.
To quantify the reduction in CV events that may be obtained with the optimal use of vascular protection therapy in Canadians at high risk of cardiovascular events.
Canadian Community Health Survey data from 2003 were used to estimate the prevalence of heart disease and/or diabetes, which were applied to an age-specific population in Canada to calculate the total number of high-risk patients. The number of events over 10 years was estimated using a state transition model, published risk equations, practice pattern data from Canadian registries and published therapy efficacy from clinical trials.
Among 2.2 million high-risk Canadians, current care with statin, ASA and ACEI therapy has reduced the estimated occurrence of CV events over the next 10 years by approximately 400,000 from 1.01 million. Universal use of combination statin, ASA and ACEI therapy for high-risk patients, compared with current care, would prevent as many as 143,000 more CV events over the next 10 years.
Great advances in the management of CV disease have been made; however, CV disease remains a substantial burden to patients and to the Canadian health care system. Canadian physicians have the opportunity to further reduce this burden through optimal management of high-risk patients based on clinical guidelines.
Notes
Cites: Can J Cardiol. 2005 Dec;21(14):1265-7116341294
Cites: Health Rep. 2005 Nov;17(1):49-5316335693
Cites: Am Heart J. 2006 May;151(5):969-7516644313
Cites: Am J Med. 2006 Aug;119(8):676-8316887414
Cites: Lancet. 2006 Aug 19;368(9536):679-8616920473
Cites: N Engl J Med. 2000 Jan 20;342(3):145-5310639539
Cites: Am Heart J. 2000 Feb;139(2 Pt 1):272-8110650300